Daunorubicin hydrochloride CAS 23541-50-6 rubidomycinhydrochloride

Payment Terms: T/T,L/C,WU
skype
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Brand: MOSINTER 
  • Name: Daunorubicin hydrochloride 
  • CAS: 23541-50-6 
  • Molecular Formula: C27H30ClNO10 
  • Molecular Weight: 563.98 
  • Specification: enterprise standard 
  • Content: >98% 
  • MP: 190°C (dec) 
  • Storage temp: -20°C 
  • Alias: rubidomycinhydrochloride 
  • Model No.: C27H30ClNO10 
  • Place of Origin: Zhejiang  
  • Min.Order: 25 Kilogram
  • Means of Transport: Land, Ocean, Air
Supply Capacity
  • Production Capacity: 1000 kg/Year
  • Packing:According to customer requirements
  • Delivery Date: Within 7 days

Daunorubicin hydrochloride (CAS: 23541-50-6)


Safety Information 

Hazard Codes 

Xn,Xi

Risk Statements 

22-40-42/43-36/37/38-20/21/22

Safety Statements 

22-36/37-45-37/39-36-26

RIDADR 

UN 2811 6.1/PG 3

WGK Germany 

3

RTECS 

HB7878000

3-10

HazardClass 

6.1(b)

PackingGroup 

III


Daunorubicin hydrochloride Usage And Synthesis

Chemical Properties

Dark Red Crystals

Usage

Antineoplastic;DNA intercaling

Usage

anti-neoplastic LD50 in mice 26 mg/kg

Usage

A DNA intercalator which may suppress acute leukemia proliferation

Usage

Anthracycline antibiotic related to the rhodomycins. Antineoplastic

General Description

Orange-red powder. Thin red needles decomposing at 188-190℃. An anti-cancer drug.

Air & Water Reactions

Water soluble.

Reactivity Profile

Daunorubicin hydrochloride may emit toxic oxides of nitrogen when heated.

Biological Activity

Anticancer agent that is clinically used to treat nonlymphocytic leukaemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo .

Preparation Products

ZORUBICIN HCL


Daunorubicin or daunomycin is chemotherapeutic of the anthracycline family that is given as a treatment for some types of cancer. It is most commonly used to treat specific types of leukemia (acute myeloid leukemia and acute lymphocytic leukemia). It was initially isolated from Streptomyces peucetius.


A liposomal formulation of daunorubicin, liposomal daunorubicin.


Uses

It slows or stops the growth of cancer cells in the body. Treatment is usually performed together with other chemotherapy medicine (such as cytarabine), and its administration depends on the type of tumor and the degree of response.


In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia.


Daunorubicin is also used as the starting material for semi-synthetic manufacturing of doxorubicin, epirubicin and idarubicin.


Mechanism of action

Similar to Doxorubicin, Daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunomycin effectively binds to every 3 base pairs and induces a local unwinding angle of 8°, but negligible distortion of helical conformation. It can also induce histone eviction from chromatin upon intercalation.


Route of administration

Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death. Daunorubicin has been used intravitreally (inside the eye) for the purposes of preventing proliferative vitreoretinopathy, a common complication following retinal detachment surgery, but has not been found to be effective and is not used for any other ophthalmic purposes at this time.

Appearance:fine powder

Packing: 25KG drum


Send message to this supplier
Mr. Fedor
Tel: +86-574-89212210
Mobile: +86-18989305995
Enter between 20 to 3,000 chatacters.
Contact Method
MOSINTER GROUP LIMITED
Guangbo Center Office 2001, YinXianDaDao 1357, Ningbo, Zhejiang, China (Mainland) / 315100
Fax: +86-574-89212215
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center